WAKEFIELD, R.I., Feb. 01, 2018 -- ChartWise Medical Systems, Inc. (www.chartwisemed.com), the award-winning industry leader in Computer-Assisted Clinical Documentation Improvement (CACDI) software, has been recognized by prominent healthcare research and analysis organization KLAS for excellence in the clinical documentation improvement technology space. For the third consecutive year, ChartWise has been named a Category Leader in the Clinical Documentation Improvement Software segment in the 2018 Best in KLAS: Software & Services report. The prestigious and highly coveted Category Leader designation is reserved for vendor solutions that lead select market segments in which at least two products meet a minimum level of KLAS Konfidence.
ChartWise set the high-water mark in the CDI Software Category with an overall KLAS score of 91.6 for the organization and its flagship ChartWise 2.0 CACDI software solution. Final KLAS scores are a composite of a detailed analysis of the industry and the products, services and technologies currently available.
“Category Leader is more than a ranking; it is a recognition of vendors committed to delivering superior solutions,” said Adam Gale, president of KLAS. “It gives voice to thousands of providers who are demanding better performance, usability and interoperability in healthcare technology.”
ChartWise recently developed a unique Risk Adjustment Factor (RAF) Calculator to provide hospitals and medical systems groundbreaking technology to measure and drive CDI processes. The CACDI software innovator is also revered for supporting quality data and accurate reimbursement through it’s advanced user interface, query library and DataScan reporting, among other features. ChartWise has also begun offering ChartWise CDI Advisory Services and a specialized CACDI MasterClass to help hospitals and medical systems maximize the value and impact of their CDI programs.
“The ChartWise team has a certain restlessness that keeps the ChartWise 2.0 solution and technology relentlessly adapting and evolving, and it means a lot to have those efforts recognized again this year in the much-anticipated Best in KLAS: Software & Services report,” said Dr. Jon Elion, founder and CEO of ChartWise Medical Systems. “ChartWise is always looking at the next feature, the next service, the next bit of data we might add to help our customers secure the insight they need to be make their CDI programs as effective and efficient as possible. The work continues and we’ll definitely be looking to continue to further advance the ChartWise 2.0 technology throughout 2018.”
For additional information about the ChartWise 2.0 product, ChartWise’s suite of CDI services or to receive a comprehensive demo of the ChartWise technology, please visit http://www.chartwisemed.com/products, or call 888-493-4502.
About ChartWise
ChartWise Medical Systems, Inc., based in Wakefield, RI, is a medical software firm and the developer of ChartWise 2.0, a web-based solution for Computer-Assisted Clinical Documentation Improvement. ChartWise 2.0's clinical intelligence expertise assists physicians and clinical documentation specialists with increased efficiencies and completeness of documentation, queries and workflow. Developed by renowned physician Jon Elion, M.D., ChartWise 2.0 is the only documentation software that translates clinical language used by physicians into accurate diagnostic language required for documentation and reimbursement. ChartWise was recognized on the 2016 and 2017 Inc. 5000 List as one of America’s fastest-growing private companies, placing first among all Rhode Island-based businesses on the list each year. ChartWise was also selected as the 2015/2016, 2017 and 2018 KLAS Award Winner for the CDI Software category, and as a 2015 Red Herring Top 100 North America and Global 100 Winner. For more information, visit www.chartwisemed.com.
About KLAS
KLAS is a data-driven company on a mission to improve the world’s healthcare by enabling provider and payer voices to be heard and counted. Working with thousands of healthcare professionals, KLAS collects insights on software, services and medical equipment to deliver reports, trending data and statistical overviews. KLAS data is accurate, honest and impartial. The research directly reflects the voice of healthcare professionals and acts as a catalyst for improving vendor performance. To learn more about KLAS and the insights we provide, visit www.KLASresearch.com
For more information contact:
David Feistel
LFPR (for ChartWise)
949.502.6200 x 224
[email protected]


DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 



